The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …

Background: Patients with chronic inflammatory disease (CID) treated with
immunosuppressive medications have increased risk for severe COVID-19. Although mRNA …

Objective To provide guidance to rheumatology providers on the use of coronavirus disease
2019 (COVID‐19) vaccines for patients with rheumatic and musculoskeletal diseases …

Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become
a high priority. Persons at risk of severe disease, for example, those receiving …

CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in
several countries. However, its immunogenicity in immunocompromised individuals has not …

Importance Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather
information on clinical outcomes and risk factors associated with morbidity and mortality in …

Background B-cell-depleting therapies increase the risk of morbidity and mortality due to
COVID-19. Evidence-based SARS-CoV-2 vaccination strategies for patients on B-cell …

Background Various observations have suggested that the course of COVID-19 might be
less favourable in patients with inflammatory rheumatic and musculoskeletal diseases …